As European markets navigate the complexities of U.S. trade tariffs and monetary policy uncertainties, investors are keenly observing how these macroeconomic factors might influence growth opportunities across the continent. In this environment, companies with substantial insider ownership often attract attention for their potential alignment of interests between management and shareholders, a factor that can be particularly reassuring during periods of economic uncertainty.

Top 10 Growth Companies With High Insider Ownership In Europe

Name Insider Ownership Earnings Growth Elicera Therapeutics (OM:ELIC) 27.8% 97.2% Vow (OB:VOW) 13.1% 120.9% Pharma Mar (BME:PHM) 11.8% 40.8% CD Projekt (WSE:CDR) 29.7% 41.3% Bergen Carbon Solutions (OB:BCS) 12% 50.8% Elliptic Laboratories (OB:ELABS) 22.6% 88.2% Ortoma (OM:ORT B) 27.7% 68.6% Nordic Halibut (OB:NOHAL) 29.8% 56.3% MedinCell (ENXTPA:MEDCL) 13.9% 114.3% Circus (XTRA:CA1) 26% 51.4%

Click here to see the full list of 229 stocks from our Fast Growing European Companies With High Insider Ownership screener.

Underneath we present a selection of stocks filtered out by our screen.

Ambu

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Ambu A/S is a medical technology company that develops, produces, and sells medical devices to hospitals, clinics, and rescue services globally with a market cap of DKK32.87 billion.

Operations: The company's revenue is primarily derived from its Disposable Medical Products segment, which generated DKK5.65 billion.

Insider Ownership: 24.9%

Ambu A/S demonstrates robust growth potential, with earnings expected to grow significantly at 25.5% annually, surpassing the Danish market average of 8.3%. Recent earnings reports show a substantial increase in net income to DKK 183 million from DKK 92 million year-on-year. The company raised its revenue growth guidance for the fiscal year and was added to the OMX Copenhagen 20 Index, reflecting positive market sentiment despite low forecasted return on equity and no recent insider trading activity.

Dive into the specifics of Ambu here with our thorough growth forecast report. Our valuation report here indicates Ambu may be overvalued.CPSE:AMBU B Ownership Breakdown as at Mar 2025

Surgical Science Sweden

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Surgical Science Sweden AB (publ) develops and markets virtual reality simulators for evidence-based medical training globally, with a market cap of SEK6.63 billion.

Operations: The company's revenue segments consist of SEK441.59 million from Industry/OEM and SEK442.50 million from Educational Products.

Insider Ownership: 26.6%

Surgical Science Sweden shows promising growth potential, with earnings forecasted to grow significantly at 37.1% annually, outpacing the Swedish market average. The company is trading below its estimated fair value and analysts agree on a potential stock price increase of 51.7%. Despite a decline in profit margins and net income for the past year, recent initiatives such as expanding into defense markets and strengthening ties with Intuitive suggest strategic positioning for future growth.

Story Continues

Navigate through the intricacies of Surgical Science Sweden with our comprehensive analyst estimates report here. Our valuation report unveils the possibility Surgical Science Sweden's shares may be trading at a discount.OM:SUS Ownership Breakdown as at Mar 2025

Vimian Group

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Vimian Group AB (publ) operates in the global animal health industry and has a market capitalization of SEK20.69 billion.

Operations: Vimian Group AB's revenue is derived from its Medtech segment (€123.90 million), Diagnostics (€20.90 million), Specialty Pharma (€172 million), and Veterinary Services (€58.20 million).

Insider Ownership: 11.1%

Vimian Group has demonstrated strong growth, with a recent earnings increase of 88.8% and fourth-quarter sales rising to €104.9 million from €82.5 million the previous year. Analysts forecast annual earnings growth of 41.5%, surpassing the Swedish market average, while revenue is expected to grow at 11.5% per year. Despite trading below its fair value estimate, insider transactions have been minimal recently, indicating cautious optimism among insiders about future prospects.

Delve into the full analysis future growth report here for a deeper understanding of Vimian Group. The valuation report we've compiled suggests that Vimian Group's current price could be inflated.OM:VIMIAN Ownership Breakdown as at Mar 2025

Next Steps

Embark on your investment journey to our 229 Fast Growing European Companies With High Insider Ownership selection here. Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Want To Explore Some Alternatives?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Companies discussed in this article include CPSE:AMBU B OM:SUS and OM:VIMIAN.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments